Drug Profile

LHW 090

Alternative Names: LHV-527; LHW090

Latest Information Update: 30 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Class Antihypertensives
Mechanism of Action Neprilysin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Resistant hypertension

Most Recent Events

19 Mar 2019 Discontinued - Phase-II for Resistant hypertension in USA, France, Denmark, Germany, Netherlands, Switzerland (PO)
10 Nov 2018 Efficacy, adverse events and pharmacodynamics data from a phase II trial in Resistant hypertension presented at the 91st Annual Scientific Sessions of the American Heart Association (AHA-2018)
11 Oct 2018 Novartis completes a phase II trial in Kidney disorders in USA and Germany (NCT02678000) (EudraCT2015-004570-15)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com